Tirosint Cost in Rhode Island 2026: Cash Price, Medicaid, Insurance & Alternatives

What Is Tirosint and Why Does It Cost More Than Standard Levothyroxine?

Tirosint is a brand-name levothyroxine formulation manufactured by IBSA Institut Biochimique SA. Each soft gel capsule contains levothyroxine sodium dissolved in an alcohol-based liquid matrix with gelatin, glycerin, and water. That formulation eliminates the excipients found in standard tablets, including acacia, lactose, and dyes, which matter clinically for patients who have celiac disease, lactose intolerance, or documented absorption problems with tablet-form levothyroxine.

Standard levothyroxine tablets are available as low-cost generics, some priced under $10 per month at major retail chains. Tirosint carries no FDA-approved generic as of early 2026, so the $230 per month list price reflects brand-only market status. The FDA approved Tirosint on December 24, 2012, under NDA 201469, for the treatment of hypothyroidism and as a pituitary TSH suppressant. [1]

Absorption variability in tablet levothyroxine is well documented. Vita et al. (Endocrine, 2014, N=45) compared liquid levothyroxine to tablet formulations in patients with absorption problems and found that liquid formulation produced significantly better TSH control (P<0.05) in patients who had conditions interfering with gastrointestinal absorption. [2] That pharmacokinetic difference is the core clinical rationale that insurers and Medicaid programs use to evaluate prior authorization requests.

The American Thyroid Association's 2014 guidelines state: "Patients with hypothyroidism who have conditions that reduce gastrointestinal absorption of levothyroxine may benefit from liquid or gel-cap formulations." [3] That recommendation gives prescribers a guideline-backed framework for the PA letter.

Tirosint Cash-Pay Price in Rhode Island: What You Will Actually Pay

The manufacturer's wholesale acquisition cost produces a retail shelf price of approximately $230 per month at Rhode Island retail pharmacies in 2026. That figure applies across major chains and independent pharmacies in Providence, Warwick, Cranston, Pawtucket, and surrounding communities.

Cash price varies modestly by pharmacy and by dose. A 50 mcg capsule and a 125 mcg capsule carry the same per-unit price at most outlets, because Tirosint is priced per capsule count rather than per microgram of active ingredient. GoodRx and similar discount aggregators show Rhode Island cash prices clustering between $215 and $240 for a 30-count supply across different dose strengths as of January 2026. [4]

No FDA-approved generic levothyroxine gel capsule exists. Because bioequivalence between tablet and gel-cap formulations is not established for regulatory substitution purposes, a pharmacist cannot legally substitute a generic tablet when a prescriber specifies Tirosint. [5] That absence of generic competition is the primary driver keeping the cash price at $230.

Patients who are uninsured or underinsured and paying cash should ask their pharmacy to run the prescription through GoodRx, RxSaver, or the IBSA direct savings program before accepting the sticker price, since these programs frequently return prices below the retail rate. [6]

Rhode Island Medicaid Coverage for Tirosint

Rhode Island Medicaid (RIte Care and Rhody Health Options) covers Tirosint with a prior authorization for patients whose hypothyroidism is complicated by malabsorption. The coverage designation is not automatic, and a prescriber must submit clinical documentation before the plan will approve the brand drug.

The prior authorization criteria generally require the prescriber to document: (1) a confirmed diagnosis of hypothyroidism per ICD-10 code E03.9 or a specific variant; (2) a comorbid condition that impairs levothyroxine absorption, such as celiac disease, short bowel syndrome, bariatric surgery history, or chronic use of proton pump inhibitors at doses shown to impair absorption; and (3) evidence of inadequate TSH control on tablet-form levothyroxine at an appropriate dose. [7]

Rhode Island's preferred drug list for thyroid agents places generic levothyroxine tablets (all manufacturers) in the first-line preferred tier. Tirosint sits in a non-preferred tier with PA. Prescribers who document the malabsorption indication clearly have a reasonable probability of approval, because the clinical literature supports gel-cap superiority in that specific population. [2]

If Medicaid denies the PA, patients have the right to a formal appeal through the Rhode Island Executive Office of Health and Human Services (EOHHS). Appeals that include a letter citing Vita et al. 2014 [2] and the ATA guideline language [3] typically perform better than appeals without clinical citations. Compounded levothyroxine from a state-licensed 503A pharmacy is a parallel option during the appeals process, discussed below.

Commercial Insurance Coverage for Tirosint in Rhode Island

Most commercial plans active in Rhode Island, including Blue Cross Blue Shield of Rhode Island, Tufts Health Plan, UnitedHealthcare, Aetna, and Cigna, place Tirosint on a non-preferred or specialty tier. Tier placement directly sets the copay structure. [8]

A non-preferred brand tier copay in Rhode Island commercial plans ranges from $60 to $120 per 30-day supply after deductible, based on 2026 plan year summaries of benefits published by major RI carriers. Patients in high-deductible health plans may pay the full negotiated rate, often $180 to $210, until the deductible is satisfied. [9]

Step therapy is common. Several RI commercial plans require documented failure or contraindication to tablet levothyroxine before they will approve Tirosint. A prescriber who writes a PA letter documenting an absorption-related diagnosis, a documented failure on tablet formulation supported by serial TSH values, and a clinical rationale citing peer-reviewed literature satisfies most step-therapy requirements. [10]

Patients should call the member services number on the back of their insurance card and ask specifically: (1) What tier is Tirosint (NDC 67234-0001-xx) on? (2) Is a prior authorization required? (3) What is the step-therapy protocol? Getting those answers before the prescription is submitted saves time.

How the IBSA Tirosint Savings Card Works in Rhode Island

IBSA offers a manufacturer savings card for Tirosint that is available to commercially insured patients who are not enrolled in a government-funded program (Medicare Part D, Medicaid, TRICARE, or any federal or state reimbursement program). Rhode Island patients who meet those criteria can use the card at participating retail pharmacies. [11]

The savings card can reduce the monthly out-of-pocket cost to as low as $0 for eligible patients, though the exact benefit depends on the plan's negotiated price and the card's current benefit cap. IBSA updates card terms annually. For 2026, patients should enroll or re-enroll through the IBSA patient support program at the IBSA website and bring the activated card to their pharmacy at the time of dispensing. [11]

Pharmacists at most Rhode Island chains, including CVS, Walgreens, Rite Aid locations, and independent compounding pharmacies that dispense commercial products, can process the savings card as a secondary claim after the primary insurance adjudication. The net patient cost appears on the pharmacy receipt.

Patients who are on Medicare Part D and cannot use the manufacturer card should ask their prescriber about the Low Income Subsidy (LIS/Extra Help) program through the Social Security Administration, which can reduce brand drug costs on Part D plans. [12]

Compounded Levothyroxine in Rhode Island: Legal Status and Cost

Compounded levothyroxine liquid and gel-cap preparations are legal in Rhode Island when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed Rhode Island prescriber. [13]

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy may compound levothyroxine in a liquid or gel-cap matrix for an individual patient if the prescriber documents a clinical need that cannot be met by a commercially available product. Rhode Island does not impose additional state-level restrictions on levothyroxine compounding beyond federal 503A requirements and Rhode Island Board of Pharmacy licensure. [14]

The cost difference is significant. Compounded levothyroxine liquid or gel-cap from a 503A pharmacy in Rhode Island costs considerably less than the $230 brand price, with many pharmacies pricing a 30-day supply in the range of $30 to $80 depending on dose, base, and dispensing fee. Some patients with specific financial situations pay as little as $0 if their prescriber writes the prescription through a pharmacy that operates on a sliding-scale or charitable basis.

Clinically, compounded preparations are not FDA-approved and are not held to the same manufacturing quality standards as Tirosint. The FDA has noted concerns about potency consistency in compounded thyroid preparations. [5] A 2013 FDA analysis found measurable potency deviations in surveyed compounded thyroid products. Patients switching from Tirosint to a compounded product should have TSH rechecked at 6 weeks after the transition, following the monitoring interval recommended in standard thyroid replacement guidelines. [3]

HealthRX Prescriber Decision Framework: Tirosint vs. Compounded Levothyroxine in Rhode Island

| Patient Scenario | Recommended Path | Monitoring Interval | |---|---|---| | Commercially insured, absorption diagnosis documented | Tirosint with PA + IBSA savings card | TSH at 6 weeks post-initiation | | RI Medicaid, malabsorption confirmed | Tirosint with PA submission citing Vita 2014 | TSH at 6 weeks; appeal if denied | | Uninsured or underinsured, cost is primary barrier | 503A compounded levothyroxine liquid | TSH at 6 weeks; recheck if formulation changes | | Medicare Part D, cannot use savings card | Tablet levothyroxine + LIS/Extra Help review | TSH at 6-8 weeks | | Celiac disease, stable TSH on tablets | Clinical reassessment before switching | TSH at 6 weeks if switch made |

Telehealth Prescribing of Tirosint in Rhode Island

Tirosint is a Schedule-exempt, non-controlled prescription drug. Rhode Island permits telehealth prescribing of non-controlled medications without requiring an in-person visit first, provided the prescriber holds a valid Rhode Island license (or an interstate compact license recognized by Rhode Island) and conducts a clinically adequate evaluation. [15]

A telehealth visit for Tirosint typically involves review of recent TSH and free T4 lab values, a medication history confirming the absorption rationale, and a prescriber assessment of clinical appropriateness. Patients must have labs drawn at a Rhode Island-accessible facility; results can be reviewed synchronously via video or asynchronously on a store-and-forward platform if the platform meets Rhode Island telehealth standards. [15]

HealthRX providers licensed in Rhode Island can prescribe Tirosint via telehealth for patients who meet clinical criteria. The prescription is sent electronically to a Rhode Island pharmacy of the patient's choice. Patients in Providence, Newport, Woonsocket, and other RI communities who cannot easily access endocrinology specialists in person find telehealth prescribing a practical route to appropriate thyroid management.

The Ryan Haight Act does not restrict Tirosint prescribing because levothyroxine is not a controlled substance under the Controlled Substances Act. [16] No DEA registration is required by the prescriber for this drug class.

How Dose Affects Tirosint Cost in Rhode Island

Tirosint is dispensed as a once-daily single capsule across available strengths: 13 mcg, 25 mcg, 37.5 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, and 150 mcg. [1] Because pricing is per capsule rather than per microgram, dose changes do not change the monthly cost at most pharmacies.

The standard full-replacement dose is 1.6 mcg/kg/day for otherwise healthy adults with complete hypothyroidism. Older patients and those with cardiac disease typically start at 12.5 to 25 mcg/day with gradual titration, as the 2014 ATA guidelines recommend. [3] Dose adjustments require repeat prescriptions, and each 30-day supply at any strength carries approximately the same $230 list price.

Patients titrating their dose should confirm with their pharmacy that the savings card or Medicaid PA covers the new strength. Insurance formularies and savings card benefits apply to the drug by NDC, and different strengths carry different NDCs. Most plans cover all strength variants under a single PA approval, but confirming this with the insurer or pharmacy prevents a gap at the point of sale. [9]

Serial TSH Monitoring and Its Interaction With Tirosint Cost

Thyroid replacement therapy requires serial TSH monitoring to confirm dose adequacy. The 2014 ATA guidelines recommend checking TSH 6 weeks after any dose initiation or change, then annually once the patient is stable. [3] Rhode Island commercial labs, including Quest Diagnostics and LabCorp locations throughout the state, process TSH panels with a typical turnaround of 24 to 48 hours. [17]

A serum TSH target of 0.5 to 2.5 mIU/L is appropriate for most adults on replacement therapy, though the ATA acknowledges that the target range should be individualized, particularly for older patients where a TSH of 1.0 to 4.0 mIU/L may be acceptable. [3] Patients switching from tablet levothyroxine to Tirosint may see TSH shift because the gel-cap formulation produces different absorption kinetics, and the magnitude of that shift was documented in Vita et al.: mean TSH decreased by 37% in patients transitioning from tablet to liquid levothyroxine (P<0.05). [2]

Persistent TSH suppression below 0.1 mIU/L on Tirosint may indicate the dose is too high or that absorption has normalized beyond what was expected. Dose reductions in that scenario carry no cost implications at a per-capsule pricing structure, provided the new strength is covered under the existing PA. [1]

Comparing Tirosint to Levothyroxine Sodium Tablets: A Cost-Benefit Perspective for RI Patients

Generic levothyroxine sodium tablets from manufacturers including Mylan, Lannett, Amneal, and Fresenius Kabi are available at Rhode Island pharmacies for as low as $4 to $10 per month for a 30-day supply under standard discount programs. [4] That price gap relative to Tirosint's $230 list price is the core financial challenge for Rhode Island patients who need the gel-cap formulation.

The clinical justification for paying the price difference rests on absorption data. A study published in Thyroid (2013) found that liquid levothyroxine produced higher peak serum T4 levels and better TSH normalization in patients taking proton pump inhibitors, compared to tablet levothyroxine taken under identical conditions (P<0.01, N=36). [18] For patients without documented absorption problems, the clinical advantage of Tirosint over a quality-controlled generic tablet is not established. [19]

Rhode Island prescribers writing Tirosint for patients without a documented absorption indication face a higher likelihood of insurance denial and no access to the clinical literature supporting the switch. Prescribers and patients in that situation should weigh the $220-per-month cost difference against any perceived benefit before requesting a PA. [8]

For patients with a genuine absorption indication, the cost of uncontrolled hypothyroidism, including cardiovascular risk, cognitive effects, and metabolic consequences, supports the case for the more expensive formulation when it produces measurably better TSH control. [20]